

해외 바이오의약품 임상 현황 (2020.12.21~2021.1.3)

한국바이오의약품협회, 2021.1.5.
출처: ClinicalTrials.gov

○ 미국 89건

NCT Number	Title	Conditions	Interventions	Sponsor/Collaborators	Phases	출처 URL
NCT04691817	Tocilizumab and Atezolizumab in Adults With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Refractory to 1st Line Immune Checkpoint Inhibitor-Based Therapy	Lung Cancer, Nonsmall Cell	Drug: Atezolizumab Drug: Tocilizumab	Abramson Cancer Center of the University of Pennsylvania Genentech, Inc.	Phase 1 Phase 2	_____
NCT04688658	Duvelisib in Combination With Nivolumab in Patients With Advanced Unresectable Melanoma	Unresectable Melanoma	Drug: Nivolumab Drug: Duvelisib	John Kirkwood Verastem, Inc. University of Pittsburgh	Phase 1 Phase 2	_____
NCT04676087	Mogamulizumab and Extracorporeal Photopheresis for the Treatment of Sezary Syndrome or Mycosis Fungoides	Mycosis Fungoides Primary Cutaneous T-Cell Non-Hodgkin Lymphoma Sezary Syndrome	Procedure: Extracorporeal Photopheresis Biological: Mogamulizumab Other: Quality-of-Life Assessment	Emory University	Phase 1 Phase 2	_____
NCT04655157	Safety and Efficacy in Participants With Metastatic BRAF-mutant Melanoma Treated With Encorafenib With and Without Binimetinib in Combination With Nivolumab and Low-dose Ipilimumab	Melanoma	Drug: encorafenib Drug: nivolumab Drug: ipilimumab Drug: binimetinib	Jason J. Luke, MD Bristol-Myers Squibb University of Pittsburgh	Phase 1 Phase 2	_____
NCT04631406	A Safety and Tolerability Study of Neural Stem Cells (NR1) in Subjects With Chronic Ischemic Subcortical Stroke (ISS)	Ischemic Stroke	Biological: Neural Stem Cells	Gary Steinberg Stanford University	Phase 1 Phase 2	_____
NCT04626635	REGN7075 in Combination With Cemiplimab in Adult Participants With Advanced Solid Tumors	Advanced Solid Tumors	Drug: REGN7075 Drug: cemiplimab	Regeneron Pharmaceuticals	Phase 1 Phase 2	_____
NCT04539236	Luspatercept and Lenalidomide (L2) in Lower-risk, Non-de[5q] MDS Patients	Myelodysplastic Syndromes	Drug: Lenalidomide Drug: Luspatercept	Mikael Sekeres MD Case Comprehensive Cancer Center	Phase 1 Phase 2	_____
NCT04512261	TOPAZ: Tucatinib in Combination With Pembrolizumab And Trastuzumab in Patients With HER2-Positive Breast Cancer Brain Metastases	Breast Cancer Brain Metastases HER2-positive Breast Cancer CNS Disease	Drug: Tucatinib Drug: Pembrolizumab Drug: Trastuzumab	Reva Basho Merck Sharp & Dohme Corp. Seagen Inc. Cedars-Sinai Medical Center	Phase 1 Phase 2	_____
NCT04482699	RAPA-501-Allo Off-the-Shelf Therapy of COVID-19	Severe COVID-19 Disease	Biological: RAPA-501-Allo off-the-shelf Therapy of COVID-19 Other: Placebo	Rapa Therapeutics LLC Hackensack Meridian Health	Phase 1 Phase 2	_____
NCT04418219	Breast Cancer Vaccine in Combination With Pembrolizumab for Treatment of Persistent, Recurrent, or Metastatic Breast Cancer	Anatomic Stage IV Breast Cancer AJCC v8 Metastatic Breast Carcinoma Prognostic Stage IV Breast Cancer AJCC v8 Recurrent Breast Carcinoma Refractory Breast Carcinoma	Drug: Cyclophosphamide Biological: Allogeneic GM-CSF-secreting Breast Cancer Vaccine SV-BR-1-GM Biological: Pembrolizumab Biological: Recombinant Interferon Alpha 2b-like Protein Other: Questionnaire Administration Other: Quality of Life Assessment	Thomas Jefferson University	Phase 1 Phase 2	_____
NCT04409080	REGN7257 in Adult Patients With Severe Aplastic Anemia That Is Refractory to or Relapsed on Immunosuppressive Therapy	Severe Aplastic Anemia (SAA)	Drug: REGN7257	Regeneron Pharmaceuticals	Phase 1 Phase 2	_____
NCT03851081	Inotuzumab Ozogamicin and Vincristine Sulfate Liposome in Treating Patients With Relapsed or Refractory CD22+ B-cell Acute Lymphoblastic Leukemia	Allogeneic Hematopoietic Stem Cell Transplantation Recipient Blasts 5 Percent or More of Bone Marrow Nucleated Cells Blasts 5 Percent or More of Peripheral Blood White Cells CD22 Positive Lymphoblasts 20 Percent or More of Bone Marrow Nucleated Cells Lymphoblasts 20 Percent or More of Peripheral Blood White Cells Recurrent B Acute Lymphoblastic Leukemia Refractory B Acute Lymphoblastic Leukemia	Biological: Inotuzumab Ozogamicin Other: Quality-of-Life Assessment Drug: Vincristine Sulfate Liposome	Roswell Park Cancer Institute Pfizer	Phase 1 Phase 2	_____
NCT03654040	Liver Transplantation With Tregs at UCSF	Liver Transplant	Biological: arTreg Procedure: leukapheresis Drug: cyclophosphamide Drug: mesna Drug: everolimus	National Institute of Allergy and Infectious Diseases (NIAID) Immune Tolerance Network (ITN)	Phase 1 Phase 2	_____
NCT02229175	Laser vs Bevacizumab Injection Alone in Treatment of Diabetic Macular Edema	Diabetic Macular Edema	Drug: bevacizumab Device: PASCAL Endpoint Management (EpM) laser treatment	University of California, San Francisco	Phase 2 Phase 3	_____
NCT04688775	Eptinezumab in Patients With Episodic Cluster Headache	Cluster Headache, Episodic	Drug: Eptinezumab Drug: Placebo	H. Lundbeck A/S	Phase 3	_____
NCT04683679	A Study of Radiation Therapy With Pembrolizumab and Olaparib in Women Who Have Triple-Negative Breast Cancer	Triple Negative Breast Cancer TNBC - Triple-Negative Breast Cancer Breast Cancer	Drug: Pembrolizumab Drug: Olaparib Radiation: Radiation	Memorial Sloan Kettering Cancer Center	Phase 2	_____
NCT04681105	Flotetuzumab for the Treatment of Relapsed or Refractory Advanced CD123-Positive Hematological Malignancies	Recurrent Acute Leukemia Recurrent B Acute Lymphoblastic Leukemia Recurrent Blastic Plasmacytoid Dendritic Cell Neoplasm Recurrent Chronic Myelogenous Leukemia, BCR-ABL1 Positive Recurrent Hairy Cell Leukemia Recurrent Hematologic Malignancy Recurrent Hodgkin Lymphoma Recurrent T Acute Lymphoblastic Leukemia Refractory Acute Leukemia Refractory B Acute Lymphoblastic Leukemia Refractory Blastic Plasmacytoid Dendritic Cell Neoplasm Refractory Chronic Myelogenous Leukemia, BCR-ABL1 Positive Refractory Hairy Cell Leukemia Refractory Hematologic Malignancy Refractory Hodgkin Lymphoma Refractory T Acute Lymphoblastic Leukemia Systemic Mastocytosis	Drug: Acetaminophen Drug: Dexamethasone Drug: Diphenhydramine Biological: Flotetuzumab Drug: Ibuprofen Drug: Ranitidine	City of Hope Medical Center National Cancer Institute (NCI)	Phase 1	_____
NCT04679311	Treatment of Angiotensin Converting Enzyme Inhibitor-induced Angioedema	Angioedema Caused by Angiotensin-Converting-Enzyme Inhibitor	Biological: High ACE Activity Fresh Frozen Plasma Other: Normal Saline	Washington University School of Medicine	Phase 2	_____
NCT04679012	Polatuzumab Vedotin in Combination With Chemotherapy in Subjects With Richter's Transformation	Richter Syndrome Chronic Lymphocytic Leukemia	Drug: Polatuzumab Vedotin Drug: Rituximab Drug: Etoposide Drug: Prednisone Drug: Cyclophosphamide Drug: Hydroxydaunomycin	Weill Medical College of Cornell University Genentech, Inc.	Phase 2	_____
NCT04678401	IS-free Treg HaploHCT	Stem Cell Transplant Complications Graft Vs Host Disease Myeloid Leukemia, Acute Myeloid Leukemia in Relapse (Disorder) Myelodysplastic Syndromes	Radiation: Radiation Drug: Fludarabine Drug: Thiotepe Drug: Cyclophosphamide Drug: Mesna Biological: Treg-enriched donor cell Biological: Unmodified donor T Cell Procedure: CD34+ Haplo Peripheral Blood Stem Cell	Dana-Farber Cancer Institute	Phase 1	_____
NCT04678336	CD123 Redirected T Cells for AML in Pediatric Subjects	Acute Myeloid Leukemia, in Relapse Acute Myeloid Leukemia, Pediatric Acute Myeloid Leukemia, Refractory	Biological: CART123 cells; cyclophosphamide; fludarabine	University of Pennsylvania	Phase 1	_____
NCT04672980	RTX-321 Monotherapy in Patients With HPV 16+ Tumors	Cervical Cancer Head and Neck Cancer Anal Cancer	Drug: RTX-321	Rubius Therapeutics	Phase 1	_____
NCT04670068	Phase I Study of Autologous CAR T-Cells Targeting the B7-H3 Antigen in Recurrent Epithelial Ovarian	Epithelial Ovarian Cancer	Drug: CAR.B7-H3 Drug: Fludarabine Drug: Cyclophosphamide	UNC Lineberger Comprehensive Cancer Center National Institutes of Health (NIH)	Phase 1	_____
NCT04666740	A Study of Pembrolizumab and Olaparib for People With Metastatic Pancreatic Ductal Adenocarcinoma and Homologous Recombination Deficiency or Exceptional Treatment Response to Platinum-Based Therapy	Metastatic Pancreatic Ductal Adenocarcinoma Homologous Recombination Deficiency (HRD)	Drug: Pembrolizumab Drug: Olaparib	Memorial Sloan Kettering Cancer Center Merck Sharp & Dohme Corp.	Phase 2	_____
NCT04665765	Polatuzumab Vedotin, Rituximab, Ifosfamide, Carboplatin, and Etoposide (PolaR-ICE) as Initial Salvage Therapy for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma	Diffuse Large B-Cell Lymphoma Unclassifiable Recurrent Diffuse Large B-Cell Lymphoma Recurrent Primary Mediastinal (Thymic) Large B-Cell Cell Lymphoma Recurrent Transformed B-Cell Non-Hodgkin Lymphoma Refractory Diffuse Large B-Cell Lymphoma Refractory Primary Mediastinal (Thymic) Large B-Cell Cell Lymphoma Refractory Transformed B-Cell Non-Hodgkin Lymphoma	Drug: Carboplatin Drug: Etoposide Drug: Ifosfamide Drug: Polatuzumab Vedotin Biological: Rituximab	City of Hope Medical Center National Cancer Institute (NCI)	Phase 2	_____
NCT04659044	Polatuzumab Vedotin, Venetoclax, and Rituximab and Hyaluronidase Human for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma	Recurrent B-Cell Non-Hodgkin Lymphoma Recurrent Grade 1 Follicular Lymphoma Recurrent Grade 2 Follicular Lymphoma Recurrent Small Lymphocytic Lymphoma Refractory B-Cell Non-Hodgkin Lymphoma Refractory Grade 1 Follicular Lymphoma Refractory Grade 2 Follicular Lymphoma Refractory Grade 3a Follicular Lymphoma Refractory Mantle Cell Lymphoma Refractory Marginal Zone Lymphoma Refractory Small Lymphocytic Lymphoma	Drug: Polatuzumab Vedotin Biological: Rituximab Biological: Rituximab and Hyaluronidase Human Drug: Venetoclax	Academic and Community Cancer Research United National Cancer Institute (NCI)	Phase 2	_____
NCT04639466	A Synthetic MVA-based SARS-CoV-2 Vaccine, COH0451, for the Prevention of COVID-19	COVID-19	Drug: Placebo Administration Biological: Vaccine Therapy	City of Hope Medical Center National Cancer Institute (NCI)	Phase 1	_____

해외 바이오의약품 임상 현황 (2020.12.21~2021.1.3)

한국바이오의약품협회, 2021.1.5.
출처: ClinicalTrials.gov

NCT04635683	Lenalidomide, Umlbrisib, and Ublituximab for the Treatment of Relapsed or Refractory Indolent Non-Hodgkin Lymphoma or Mantle Cell Lymphoma	Recurrent B-Cell Non-Hodgkin Lymphoma Recurrent Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue Recurrent Follicular Lymphoma Recurrent Grade 1 Follicular Lymphoma Recurrent Grade 2 Follicular Lymphoma Recurrent Grade 3a Follicular Lymphoma Recurrent Lymphoplasmacytic Lymphoma Recurrent Mantle Cell Lymphoma Recurrent Marginal Zone Lymphoma Recurrent Nodal Marginal Zone Lymphoma Recurrent Splenic Marginal Zone Lymphoma Recurrent Waldenstrom Macroglobulinemia Refractory B-Cell Non-Hodgkin Lymphoma Refractory Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue Refractory Follicular Lymphoma Refractory Grade 1 Follicular Lymphoma Refractory Grade 2 Follicular Lymphoma Refractory Grade 3a Follicular Lymphoma Refractory Lymphoplasmacytic Lymphoma Refractory Mantle Cell Lymphoma Refractory Marginal Zone Lymphoma Refractory Nodal Marginal Zone Lymphoma Refractory Splenic Marginal Zone Lymphoma Refractory Waldenstrom Macroglobulinemia	Drug: Lenalidomide Biological: Ublituximab Drug: Umlbrisib	Yazeed Sawalha Ohio State University Comprehensive Cancer Center	Phase 1	—
NCT04634513	Shigella CVD 31000: Study of Responses With Shigella-ETEC Vaccine Strain CVD 12085-122	Shigella Infection Enterotoxigenic Escherichia Coli Infection	Biological: strain CVD 12085-122 Other: Placebo	University of Maryland, Baltimore	Phase 1	—
NCT04595890	Knee Injections for the Clinical Management of Knee Osteoarthritis	Knee Osteoarthritis	Biological: Autologous Nucleated Cells	University of Delaware	Phase 2	—
NCT04573140	A Study of RNA-lipid Particle (RNA-LP) Vaccines for Newly Diagnosed Pediatric High-Grade Gliomas (pHGG) and Adult Glioblastoma (GBM)	Adult Glioblastoma	Biological: Autologous total tumor mRNA and pp65 full length (fl) lysosomal associated membrane protein (LAMP) mRNA loaded DOTAP liposome vaccine administered intravenously (RNA loaded lipid particles, RNA-LPs)	University of Florida Pacific Pediatric Neuro-Oncology Consortium University of California, San Francisco CureSearch	Phase 1	—
NCT04572451	Safety of SBRT With Anti-PD1 and Anti-IL-8 for the Treatment of Multiple Metastases in Advanced Solid Tumors	Melanoma Carcinoma, Renal Cell Unresectable Solid Tumors	Drug: nivolumab Drug: BMS-986253 Radiation: Stereotactic Body Radiotherapy (SBRT)	Jason J. Luke, MD Bristol-Myers Squibb University of Pittsburgh	Phase 1	—
NCT04535817	Xolair Interventional Study in ASD Patients With Comorbid Atopy	Autism Spectrum Disorder Atopy	Drug: Omalizumab Injection [Xolair]	Beth Israel Deaconess Medical Center Novartis	Phase 1	—
NCT04521946	Chemotherapy and Donor Stem Transplant for the Treatment of Patients With High Grade Brain Cancer	Anaplastic Ependymoma Atypical Teratoid/Rhabdoid Tumor Central Nervous System Germ Cell Tumor Choroid Plexus Carcinoma Intracranial Myeloid Sarcoma Malignant Brain Neoplasm Malignant Glioma Medulloblastoma Primitive Neuroectodermal Tumor Recurrent Anaplastic Ependymoma Recurrent Atypical Teratoid/Rhabdoid Tumor Recurrent Malignant Brain Neoplasm Recurrent Malignant Glioma Recurrent Medulloblastoma Recurrent Primitive Neuroectodermal Tumor	Drug: Etoposide Drug: Fludarabine Phosphate Procedure: Hematopoietic Cell Transplantation Biological: Lapine T-Lymphocyte Immune Globulin Drug: Melphalan Drug: Mycophenolate Mofetil Drug: Tacrolimus Drug: Thiotepa	M.D. Anderson Cancer Center National Cancer Institute (NCI)	Phase 1	—
NCT04512287	PRP for Treatment of Peyronie's Disease	Peyronie Disease Sexual Dysfunction, Physiological Sexual Dysfunction Male Genital Diseases, Male	Drug: Autologous Platelet Rich Plasma Other: Saline Solution	University of Miami	Phase 2	—
NCT04498325	Evaluating the Effect of NT-17, a Long Acting Interleukin-7, to Increase Lymphocyte Counts and Enhance Immune Clearance of SARS-CoV-2 (COVID-19)	COVID-19 SARS-CoV-2	Drug: NT-17 Drug: Placebo Procedure: Blood for research purposes Procedure: Blood for pharmacokinetic samples Procedure: Nasopharyngeal, oropharyngeal, or saliva swab Procedure: Blood for anti-drug antibody (ADA)	Washington University School of Medicine Neolimmune Tech	Phase 1	—
NCT04493060	Niraparib and Dostarlimab for the Treatment of Germline or Somatic BRCA1/2 and PALB2 Mutated Metastatic Pancreatic Cancer	Metastatic Pancreatic Ductal Adenocarcinoma Stage IV Pancreatic Cancer AJCC v8	Biological: Dostarlimab Drug: Niraparib	Mayo Clinic National Cancer Institute (NCI)	Phase 2	—
NCT04486781	A Study of Pembrolizumab+ sEphB4 in Metastatic Urothelial Carcinoma	Metastatic Urothelial Carcinoma	Drug: Pembrolizumab + sEphB4-HSA	Vasgene Therapeutics, Inc	Phase 2	—
NCT04484077	hCT-MSC Infusion in Adults With Autism Spectrum Disorder	Autism Spectrum Disorder Autism	Biological: hCT-MSC	Joanne Kurtzberg, MD The Marcus Foundation Duke University	Phase 1	—
NCT04466566	A Study to Evaluate the Effect of Genetic Variation on Beta-cell Function During Fasting and Hyperglycemia in Nondiabetics	Healthy	Other: Saline Biological: Exendin-9,39	Adrian Vella National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) Mayo Clinic	Phase 3	—
NCT04465643	Neoadjuvant Nivolumab Plus Ipilimumab for Newly Diagnosed Malignant Peripheral Nerve Sheath Tumor	Nerve Sheath Tumors	Drug: Nivolumab Drug: Ipilimumab	Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins Bristol-Myers Squibb	Phase 1	—
NCT04459338	A Dose-response Study Examining the Contribution of GLP-1 Receptor Signaling to Glucagon-stimulated Insulin Secretion	Healthy	Biological: Exendin-9,39 Other: Saline	Adrian Vella National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) Mayo Clinic	Phase 3	—
NCT04430452	Hypofractionated Radiotherapy Followed by Durvalumab With or Without Tremelimumab for the Treatment of Liver Cancer After Progression on Prior PD-1 Inhibition	Advanced Hepatocellular Carcinoma Stage III Hepatocellular Carcinoma AJCC v8 Stage IIIA Hepatocellular Carcinoma AJCC v8 Stage IIIB Hepatocellular Carcinoma AJCC v8 Stage IV Hepatocellular Carcinoma AJCC v8 Stage IVA Hepatocellular Carcinoma AJCC v8 Stage IVB Hepatocellular Carcinoma AJCC v8	Biological: Durvalumab Radiation: Hypofractionated Radiation Therapy Biological: Tremelimumab	Mary Feng, MD Astrazeneca University of California, San Francisco	Phase 2	—
NCT04417660	Bintrafusp Alfa (M7824) in Subjects With Thymoma and Thymic Carcinoma	Thymic Epithelial Tumor Recurrent Thymoma Thymic Cancer	Drug: M7824	National Cancer Institute (NCI) National Institutes of Health Clinical Center (CC)	Phase 2	—
NCT04406064	Viral Specific T-cells for Treatment of COVID-19	Viral Infection	Biological: Viral Specific T-cells (VSTs)	Children's Hospital Medical Center, Cincinnati Hoxworth Blood Center	Phase 2	—
NCT04377932	Interleukin-15 Armored Glypican 3-specific Chimeric Antigen Receptor Expressed in T Cells for Pediatric Solid Tumors	Liver Cancer Rhabdomyosarcoma Malignant Rhabdoid Tumor Liposarcoma Wilms Tumor Yolk Sac Tumor	Genetic: AGAR T cells Drug: Cytosine Drug: Fludara	Baylor College of Medicine Center for Cell and Gene Therapy, Baylor College of Medicine	Phase 1	—
NCT04372615	The EXTINGUISH Trial of Inebilizumab in NMDAR Encephalitis	Autoimmune Encephalitis Encephalitis	Drug: Inebilizumab Drug: Placebo	University of Utah	Phase 2	—
NCT04354025	Cytokine-induced Memory-like NK Cells in Combination With Chemotherapy in Pediatric Patients With Refractory or Relapsed AML	Refractory Acute Myeloid Leukemia Relapsed Acute Myeloid Leukemia	Biological: Cytokine induced memory-like NK cells Drug: Fludarabine Drug: Ara-C Drug: G-CSF Drug: Interleukin-2 Procedure: Leukapheresis	Washington University School of Medicine	Phase 2	—
NCT04334408	Safety and Efficacy of Fremanezumab for Migraine in Adult CADASIL	Cadasil Migraine	Drug: Fremanezumab Drug: Placebo	Mayo Clinic	Phase 2	—
NCT04302324	A Phase II Study of Daratumumab, Clarithromycin, Pomalidomide And Dexamethasone (D-ClaPd) In Multiple Myeloma Patients Previously Exposed to Daratumumab	Multiple Myeloma Refractory Multiple Myeloma Relapse Multiple Myeloma	Drug: Daratumumab Drug: Clarithromycin Drug: Pomalidomide Drug: Dexamethasone	Weill Medical College of Cornell University Janssen Scientific Affairs, LLC	Phase 2	—
NCT04301778	Durvalumab in Combination With a CSF-1R Inhibitor (SNDX-6532) Following Chemo or Radio-Embolization for Patients With Intrahepatic Cholangiocarcinoma	Unresectable Intrahepatic Cholangiocarcinoma	Drug: Durvalumab Drug: SNDX-6532	Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins Syndax Pharmaceuticals AstraZeneca	Phase 2	—
NCT04280471	Fecal Microbiota Transplantation for the Treatment of Severe Acute Gut Graft-Versus-Host Disease	Acute Graft Versus Host Disease Gastrointestinal Tract Acute Graft Versus Host Disease Severe Gastrointestinal Tract Acute Graft Versus Host Disease Steroid Resistant Gastrointestinal Tract Acute Graft Versus Host Disease	Drug: Fecal Microbiota Transplantation Capsule	Jonsson Comprehensive Cancer Center	Phase 1	—
NCT04274166	Secukinumab for the Inflammatory Phase of Pyoderma Gangrenosum	Pyoderma Gangrenosum	Drug: secukinumab 150 mg (2 injections per dose)	Wake Forest University Health Sciences Novartis	Phase 2	—
NCT04190056	Pembrolizumab and Tamoxifen With or Without Vorinostat for the Treatment of Estrogen Receptor Positive Breast Cancer	Anatomic Stage IV Breast Cancer AJCC v8 Prognostic Stage IV Breast Cancer AJCC v8	Biological: Pembrolizumab Drug: Tamoxifen Drug: Vorinostat	University of California, San Francisco Merck Sharp & Dohme Corp.	Phase 2	—
NCT04150692	Escalation of Daratumumab Frequency Following Biochemical Progression in Relapsed/Refractory Multiple Myeloma	Multiple Myeloma	Biological: Dara-SC Procedure: Blood for research assessments Procedure: Bone marrow for research assessments	Washington University School of Medicine Janssen, LP	Phase 2	—
NCT04149821	Umlbrisib Plus Ublituximab (U2) in Progressive CLL After Novel Therapy	Chronic Lymphocytic Leukemia CLL Progression CLL/SLL	Drug: Umlbrisib Drug: Ublituximab	Weill Medical College of Cornell University TG Therapeutics, Inc.	Phase 2	—
NCT04093323	Polarized Dendritic Cell (aDC1) Vaccine, Interferon Alpha-2, Rintatolimod, and Celecoxib for the Treatment of HLA-A2+ Refractory Melanoma	HLA-A2 Positive Cells Present Refractory Melanoma	Biological: Alpha-type-1 Polarized Dendritic Cells Drug: Celecoxib Drug: PD-1 Ligand Inhibitor Drug: PD1 Inhibitor Biological: Recombinant Interferon Alfa-2b Drug: Rintatolimod	Roswell Park Cancer Institute	Phase 2	—
NCT03943901	Split-Dose R-CHOP for Older Adults With DLBCL	Diffuse Large B Cell Lymphoma DLBCL Cancer	Drug: Rituximab Drug: Cyclophosphamide Drug: Doxorubicin Drug: Vincristine Drug: Prednisone Biological: Pegfilgrastim	University of Wisconsin, Madison Medical College of Wisconsin	Phase 2	—

해외 바이오의약품 임상 현황 (2020.12.21~2021.1.3)

한국바이오의약품협회, 2021.1.5.
출처: ClinicalTrials.gov

NCT03810911	Mechanisms of EPO-induced Hypertension	Chronic Kidney Disease Blood Pressure Anemia	Drug: Darbepoetin	VA Office of Research and Development	Phase 2	
NCT03617445	Fecal Microbiota Transplantation for C. Difficile Infection in Solid Organ Transplant Recipients	Clostridium Difficile Infection Recurrence	Drug: FMT enema Drug: Oral Vancomycin Drug: FMT enema placebo Drug: Oral Vancomycin placebo	University of Wisconsin, Madison	Phase 2	
NCT03463239	Bioengineered Penile Tissue Constructs for Irreversibly Damaged Penile Corpora	Urologic Diseases Male Urogenital Diseases Penile Diseases Corpus Callosum Malformation Corpora Cavemosa; Inflammation Trauma Injury	Biological: Autologous tissue engineered corpora	Wake Forest University Health Sciences United States Department of Defense	Phase 1	
NCT03361852	A Pilot Study of a Personalized Neoantigen Cancer Vaccine Following Front-Line Rituximab in Follicular Lymphoma	Follicular Lymphoma	Drug: Rituximab Biological: Neo Vax	Dana-Farber Cancer Institute	Phase 1	
NCT03219450	A Personalized Neoantigen Cancer Vaccine in Treatment Naïve, Asymptomatic Patients With IGHV Unmutated CLL	Lymphocytic Leukemia	Drug: NeoVax Drug: Cyclophosphamide Drug: Pembrolizumab	Dana-Farber Cancer Institute Oncovir, Inc. BioNTech SE Merck Sharp & Dohme Corp.	Phase 1	
NCT02847949	A Study of IGN002 for Refractory NHL	NHL	Biological: IGN002	Spectrum Pharmaceuticals, Inc The Leukemia and Lymphoma Society	Phase 1	
NCT02200718	A Study of NeuroVax™ a Novel Therapeutic TCR Peptide Vaccine for Pediatric Multiple Sclerosis	Multiple Sclerosis	Biological: NeuroVax Biological: IFA Incomplete Freund's Adjuvant	Immune Response BioPharma, Inc.	Phase 1	
NCT04660929	CAR-macrophages for the Treatment of HER2 Overexpressing Solid Tumors	HER2-positive Adenocarcinoma Bile Duct Cancer Biliary Tract Cancer Bladder Cancer Breast Cancer Breast Neoplasm Carcinoma, Ductal Carcinoma, Hepatocellular Cancer Carcinoma, Non-Small-Cell Lung Carcinoma, Ovarian Epithelial Carcinoma, Small Cell Carcinoma, Squamous Carcinoma, Transitional Cell Colorectal Cancer Esophagogastric Junction Neoplasms Inflammatory Breast Cancer Stomach Neoplasms Malignant Neoplasms Ovarian Neoplasms Pancreatic Cancer HER2-positive Solid Tumors HER2-positive Breast Cancer HER2-positive Gastric Cancer HER-2 Protein Overexpression HER-2 Gene Amplification	Biological: CT-0508	Carisma Therapeutics Inc	Phase 1	
NCT04620187	Post-op T-DM1 in HER-2+ Salivary Gland Carcinomas	Salivary Gland Cancer HER2 Gene Mutation	Drug: Ado-trastuzumab (T) emtansine (T-DM1) Radiation: Standard of Care Radiotherapy Drug: Standard of Care Chemotherapy	Dana-Farber Cancer Institute Genentech, Inc.	Phase 2	
NCT04563520	SAFE Study: Safety of aPCC Following Emicizumab Prophylaxis	Hemophilia A	Drug: aPCC-emicizumab Drug: FEIBA Drug: SEVENFACT	Emory University Takeda Pharmaceuticals North America, Inc.	Phase 3	
NCT04551430	Cabozantinib Combined With PD-1 and CTLA-4 Inhibition in Metastatic Soft Tissue Sarcoma	Metastatic Soft-tissue Sarcoma	Drug: Cabozantinib Drug: Nivolumab Drug: Ipilimumab	Washington University School of Medicine Exelixis Bristol-Myers Squibb	Phase 2	
NCT04483206	Personalized Autologous Transplant for Multiple Myeloma	Plasma Cell Myeloma	Procedure: Autologous Hematopoietic Stem Cell Transplantation Drug: Melphalan Other: Questionnaire Administration	Emory University National Cancer Institute (NCI)	Phase 1	
NCT03607955	Paclitaxel + Carboplatin With AVB-S6-500 in Women With Stage III or IV Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer Receiving Neoadjuvant Chemotherapy	Epithelial Ovarian Cancer Primary Peritoneal Carcinoma Fallopian Tube Cancer	Drug: AVB-S6-500 Drug: Paclitaxel Drug: Carboplatin Procedure: Tissue from Diagnostic Laparoscopy Procedure: Tissue from Core biopsy Procedure: Interval Debulking Procedure: Peripheral blood Procedure: Ascites collection	Washington University School of Medicine Aravive, Inc.	Phase 1	
NCT04537377	A Phase I/II Study of VTX-801 in Adult Patients With Wilson's Disease	Wilson's Disease	Genetic: VTX-801	Vivet Therapeutics SAS	Phase 1 Phase 2	
NCT04680065	GDNF Gene Therapy for Multiple System Atrophy	Multiple System Atrophy	Biological: AAV2-GDNF gene therapy Procedure: Sham (Placebo) Surgery	Brain Neurotherapy Bio, Inc.	Phase 1	
NCT03993106	A Study of sEphB4-HSA in Kaposi Sarcoma An Open-label Study Using ASP-1929	Kaposi Sarcoma	Drug: sEphB4-HSA	Vasgene Therapeutics, Inc	Phase 2	
NCT04305795	Photoimmunotherapy in Combination With Anti-PD1 Therapy in EGFR Expressing Advanced Solid Tumors	Recurrent Head and Neck Squamous Cell Carcinoma Metastatic Head-and-neck Squamous-cell Carcinoma Locally Advanced Cutaneous Squamous Cell Carcinoma Metastatic Cutaneous Squamous Cell Carcinoma	Biological: 200 mg Pembrolizumab Biological: Cemiplimab 350mg Combination Product: ASP-1929	Rakuten Medical, Inc.	Phase 1 Phase 2	
NCT04476901	Transcatheter Injection of Allogeneic- MSC in Patients With Non-Ischemic Dilated Cardiomyopathy	Non-ischemic Dilated Cardiomyopathy	Biological: allogeneic human mesenchymal stem cells (hMSCs) Other: Placebo	Joshua M Hare United States Department of Defense The University of Texas Health Science Center, Houston University of Miami	Phase 2	
NCT04488354	Long-term Follow-up Study for Patients Treated With CLBR001 CAR-T	Relapsed/Refractory B-cell Lymphomas Diffuse Large B-Cell Lymphoma (DLBCL) Follicular Lymphoma (FL) Chronic Lymphocytic Leukemia (CLL) Marginal Zone Lymphoma (MZL) Mantle Cell Lymphoma (MCL) Small Lymphocytic Lymphoma (SLL) Primary Mediastinal Large B Cell Lymphoma Transformed Follicular Lymphoma	Combination Product: CLBR001 and SW1019	Calibr, a division of Scripps Research	Phase 1	
NCT04676477	Patritumab Deruxtecane in Combination With Osimertinib in Subjects With Locally Advanced or Metastatic EGFR-mutated Non-Small Cell Lung Cancer	Non-Small Cell Lung Cancer (NSCLC)	Drug: Patritumab deruxtecane Drug: Osimertinib	Daiichi Sankyo, Inc.	Phase 1	
NCT04632992	A Study Evaluating Targeted Therapies in Participants Who Have Advanced Solid Tumors With Genomic Alterations or Protein Expression Patterns Predictive of Response	Advanced Unresectable or Metastatic Solid Malignancy	Drug: Entrectinib Drug: GDC-0077 Drug: Alectinib Drug: Ipatasertib Drug: Atezolizumab Drug: Trastuzumab Emtansine Drug: Pertuzumab, Trastuzumab, and Hyaluronidase-zzzf Drug: Tucatinib Drug: Investigator's Choice of Chemotherapy	Genentech, Inc.	Phase 2	
NCT04629248	A Study Evaluating the Efficacy and Safety of Obinituzumab in Participants With Primary Membranous Nephropathy	Primary Membranous Nephropathy	Drug: Obinituzumab Drug: Tacrolimus Drug: Methylprednisolone Drug: Acetaminophen Drug: Diphenhydramine	Hoffmann-La Roche	Phase 3	
NCT04660760	Ramucirumab and Trifluridine/Tipiracil or Paclitaxel for the Treatment of Patients With Previously Treated Advanced Gastric or Gastroesophageal Junction Cancer	Clinical Stage III Gastric Cancer AJCC v8 Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8 Clinical Stage IV Gastric Cancer AJCC v8 Clinical Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8 Clinical Stage IVA Gastric Cancer AJCC v8 Clinical Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8 Clinical Stage IVB Gastric Cancer AJCC v8 Clinical Stage IVB Gastroesophageal Junction Adenocarcinoma AJCC v8 Locally Advanced Unresectable Gastric Adenocarcinoma Locally Advanced Unresectable Gastroesophageal Junction Adenocarcinoma Metastatic Gastric Adenocarcinoma Metastatic Gastroesophageal Junction Adenocarcinoma Pathologic Stage III Gastric Cancer AJCC v8 Pathologic Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8 Pathologic Stage IIIA Gastric Cancer AJCC v8 Pathologic Stage IIIA Gastroesophageal Junction Adenocarcinoma AJCC v8 Pathologic Stage IIIB Gastric Cancer AJCC v8 Pathologic Stage IIIB Gastroesophageal Junction Adenocarcinoma AJCC v8 Pathologic Stage IIIC Gastric Cancer AJCC v8 Pathologic Stage IV Gastric Cancer AJCC v8 Pathologic Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8 Pathologic Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8 Pathologic Stage IVB Gastroesophageal Junction Adenocarcinoma AJCC v8 Postneoadjuvant Therapy Stage III Gastric Cancer AJCC v8 Postneoadjuvant Therapy Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8 Postneoadjuvant Therapy Stage IIIA Gastroesophageal Junction Adenocarcinoma AJCC v8 Postneoadjuvant Therapy Stage IIIB Gastric Cancer AJCC v8 Postneoadjuvant Therapy Stage IV Gastric Cancer AJCC v8 Postneoadjuvant Therapy Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8 Postneoadjuvant Therapy Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8 Postneoadjuvant Therapy Stage IVB Gastroesophageal Junction Adenocarcinoma AJCC v8	Drug: Paclitaxel Other: Quality-of-Life Assessment Biological: Ramucirumab Drug: Trifluridine and Tipiracil Hydrochloride	Academic and Community Cancer Research United National Cancer Institute (NCI)	Phase 2	
NCT04611802	A Study Looking at the Efficacy, Immune Response, and Safety of a COVID-19 Vaccine in Adults at Risk for SARS-CoV-2	SARS-CoV Infection Covid19	Biological: SARS-CoV-2 rS/Matrix-M1 Adjuvant Other: Placebo	Novavax Department of Health and Human Services	Phase 3	
NCT04607421	BRAF V600E-mutant Colorectal Cancer Study of Encorafenib Taken With Cetuximab Plus or Minus Chemotherapy (BREAKWATER)	Neoplasms	Drug: Encorafenib Drug: Cetuximab Drug: Oxaliplatin Drug: Irinotecan Drug: Leucovorin Drug: 5-FU Drug: Capecitabine Drug: Bevacizumab	Pfizer Ono Pharmaceutical Co. Ltd Merck KGaA, Darmstadt, Germany	Phase 3	
NCT04634253	A Study of LY3462817 in Participants With Rheumatoid Arthritis	Rheumatoid Arthritis	Drug: Placebo Drug: LY3462817	Eli Lilly and Company	Phase 2	
NCT04609566	Brentuximab Vedotin With Pembrolizumab in Metastatic Solid Tumors	Melanoma Non-small Cell Lung Cancer	Drug: brentuximab vedotin Drug: pembrolizumab	Seagen Inc Merck Sharp & Dohme Corp.	Phase 2	

해외 바이오의약품 임상 현황 (2020.12.21~2021.1.3)

한국바이오의약품협회, 2021.1.5.
출처: ClinicalTrials.gov

NCT04592341	A Study to Evaluate the Pharmacodynamic (PD) Effects of Once Weekly Administration of Gantenerumab in Participants With Early Alzheimer's Disease (AD)	Alzheimer Disease	Drug: Gantenerumab	Hoffmann-La Roche	Phase 2	——
NCT04560569	Albuvirtide in Combination With 3BNC117 in Patients With Multi-Drug Resistant (MDR) HIV-1 Infection	HIV/AIDS	Drug: Albuvirtide Drug: 3BNC117 Antibody	Frontier Biotechnologies Inc.	Phase 2	——
NCT04416451	Study of Rituximab and Venetoclax in People With Newly Diagnosed Marginal Zone Lymphoma	Marginal Zone Lymphoma	Drug: Rituximab Drug: Venetoclax	Memorial Sloan Kettering Cancer Center AbbVie	Phase 2	——
NCT04639219	A Study of T-DXd for the Treatment of Solid Tumors Harboring HER2 Activating Mutations	Advanced Solid Tumors With HER2 Mutation	Drug: Trastuzumab deruxtecan	AstraZeneca Daiichi Sankyo Co., Ltd.	Phase 2	——

○ 영국 2건

NCT Number	Title	Conditions	Interventions	Sponsor/Collaborators	Phases	출처 URL
NCT04690335	Human Challenge Study to Evaluate the Efficacy of MV-012-968 Vaccine	RSV Infection	Biological: MV-012-968 Other: Placebo	Meissa Vaccines, Inc. Hvivo	Phase 2	——
NCT04592341	A Study to Evaluate the Pharmacodynamic (PD) Effects of Once Weekly Administration of Gantenerumab in Participants With Early Alzheimer's Disease (AD)	Alzheimer Disease	Drug: Gantenerumab	Hoffmann-La Roche	Phase 2	——

○ 프랑스 6건

NCT Number	Title	Conditions	Interventions	Sponsor/Collaborators	Phases	출처 URL
NCT04678362	TALazoparib and Avelumab as Maintenance Therapy in Platinum-Sensitive Metastatic or Locally Advanced Urothelial Carcinoma	Urothelial Carcinoma	Drug: Talazoparib + Avelumab	Centre Francois Baclesse Pfizer	Phase 2	——
NCT04547504	pEmbrolizumab verSus chemotherapy and pEmbrolizumab in Non-small-cell Lung Cancers (NSCLC) With PDL1 ≥ 50 %	Non-small-cell Lung Cancer	Drug: Pembrolizumab Drug: Pembrolizumab and Chemotherapy drugs	University Hospital, Brest Groupe Francais de Pneumo-Cancérologie	Phase 3	——
NCT03915678	Atezolizumab Combined With BDB001 And Immunogenic Radiotherapy in Patients With Advanced Solid Tumors	Solid Tumor, Adult Pancreatic Cancer Virus-associated Tumors Non Small Cell Lung Cancer Melanoma Bladder Cancer Triple Negative Breast Cancer	Drug: Association atezolizumab + BDB001 + RT Drug: Association atezolizumab + BDB001 + RT	Institut Bergonié Roche Pharma AG National Cancer Institute, France Seven and Eight Biopharmaceuticals Inc	Phase 2	——
NCT04629248	A Study Evaluating the Efficacy and Safety of Obinutuzumab in Participants With Primary Membranous Nephropathy	Primary Membranous Nephropathy	Drug: Obinutuzumab Drug: Tacrolimus Drug: Methylprednisolone Drug: Acetaminophen Drug: Diphenhydramine	Hoffmann-La Roche	Phase 3	——
NCT04592341	A Study to Evaluate the Pharmacodynamic (PD) Effects of Once Weekly Administration of Gantenerumab in Participants With Early Alzheimer's Disease (AD)	Alzheimer Disease	Drug: Gantenerumab	Hoffmann-La Roche	Phase 2	——
NCT04432389	Study to Assess the Efficacy and Safety of Allogeneic Osteoblastic Cells (ALLOB®) Single Implantation in Tibial Fracture	Tibial Fracture	Biological: ALLOB Other: placebo	Bone Therapeutics S.A ICON plc	Phase 2	——

○ 독일 4건

NCT Number	Title	Conditions	Interventions	Sponsor/Collaborators	Phases	출처 URL
NCT04688385	Personalized Multi-peptide Vaccination in CLL Patients	Chronic Lymphocytic Leukemia	Biological: Multi-peptide Vaccine+ XS15	University Hospital Tuebingen	Phase 1	——
NCT04681430	Reconvalescent Plasma/Camostat Mesylate Early in SARS-CoV-2 Q-PCR (COVID-19) Positive High-risk Individuals	Corona Virus Infection SARS-CoV-2 Infection SARS-CoV-2 PCR Test Positive SARS-CoV-2 Acute Respiratory Disease	Biological: Convalescent plasma Drug: Camostat Mesilate Drug: Placebo for Camostat Mesilate Other: Standard of Care (SoC)	Heinrich-Heine University, Dusseldorf The Federal Ministry of Health, Germany (Bundesministerium für Gesundheit, BMG)	Phase 2	——
NCT04432389	Study to Assess the Efficacy and Safety of Allogeneic Osteoblastic Cells (ALLOB®) Single Implantation in Tibial Fracture	Tibial Fracture	Biological: ALLOB Other: placebo	Bone Therapeutics S.A ICON plc	Phase 2	——
NCT04592341	A Study to Evaluate the Pharmacodynamic (PD) Effects of Once Weekly Administration of Gantenerumab in Participants With Early Alzheimer's Disease (AD)	Alzheimer Disease	Drug: Gantenerumab	Hoffmann-La Roche	Phase 2	——

○ 중국 19건

NCT Number	Title	Conditions	Interventions	Sponsor/Collaborators	Phases	출처 URL
NCT04690192	CNCT19 Following ASCT in Patients With Relapsed or Refractory B-cell Lymphoma	Large B-cell Lymphoma	Biological: CNCT19 Drug: Gemcitabine Injection Drug: busulfan Drug: Melphalan Injection	Zou Dehui Juventas Cell Therapy Ltd. Institute of Hematology & Blood Diseases Hospital	Phase 1 Phase 2	——
NCT04687657	Umbilical Cord Blood Transfusion in Consolidation Therapy of Elderly Patients With Acute Myeloid Leukemia	Leukemia, Myelomonocytic, Acute	Drug: umbilical cord blood	First Affiliated Hospital Xi'an Jiaotong University	Phase 1	——
NCT04683965	Pemetrexed and TAS-102 in Combination With Bevacizumab in Refractory Colorectal Cancer	Colorectal Neoplasms	Drug: Pemetrexed Drug: TAS-102 Drug: Bevacizumab	The First Affiliated Hospital with Nanjing Medical University Jiangsu HanSoh Pharmaceutical Group Co., Ltd	Phase 2	——
NCT04675983	A Study of Sintilimab Plus Ramucirumab as First-line Treatment for G/EGJ Adenocarcinoma (ORIENT-106)	Gastric Adenocarcinoma	Drug: Sintilimab Drug: Ramucirumab Drug: Cisplatin Drug: 5-fluorouracil Drug: Oxaliplatin Drug: Capecitabine	Innovent Biologics (Suzhou) Co. Ltd.	Phase 3	——
NCT04670978	Abraxane With Bevacizumab Biosimilar in Patients With Recurrent, Platinum-resistant Epithelial Ovarian Cancer	Objective Response Rate	Drug: albumin-bound paclitaxel combined with bevacizumab biosimilar	Shandong University	Phase 2	——
NCT04668365	Zanubrutinib Combined With Standard Chemotherapy in the Treatment for Patients With Diffuse Large B Cell Lymphoma	Diffuse Large B Cell Lymphoma CD79A Gene Mutation CD79B Gene Mutation	Drug: Rituximab Drug: Zanubrutinib Drug: Cyclophosphamide Drug: Epirubicin Drug: Vincristine Drug: Prednisone	Henan Cancer Hospital	Phase 2	——
NCT04653480	Surufatinib, Toripalimab and Chemotherapy in Second-line MT and MSS CRC	Colorectal Cancer Antiangiogenesis Immunotherapy	Drug: Surufatinib Drug: Toripalimab Drug: chemotherapy	Zhejiang University	Phase 2	——
NCT04650633	SHR-1701 in Patients With Recurrent/Metastatic ScchN	Squamous Cell Carcinoma of Head and Neck	Drug: SHR-1701	Jiangsu HengRui Medicine Co., Ltd.	Phase 2	——
NCT04639271	Pyrotinib, Trastuzumab And Abraxane in HER2-positive MBC With Brain Metastasis	Breast Cancer HER2-positive Breast Cancer	Drug: Pyrotinib Plus And Drug: Trastuzumab Drug: Abraxane	Shandong Cancer Hospital and Institute	Phase 2	——
NCT04622566	Lenvatinib and Pembrolizumab in Resectable Mucosal Melanoma	Mucosal Melanoma Neoadjuvant Treatment	Drug: Lenvatinib, Pembrolizumab	Beijing Cancer Hospital	Phase 2	——
NCT04591275	Clinical Efficacy and Safety Comparative Study Between CMAB807 Injection and Prolia®	Postmenopausal Osteoporosis	Drug: CMAB807 Injection Drug: Prolia®	Shanghai Biomabs Pharmaceutical Co., Ltd.	Phase 3	——
NCT04574817	Study of HX008 for the Treatment of Anaplastic Thyroid Cancer (ATC)	Anaplastic Thyroid Cancer	Drug: HX008	Taizhou Hanzhong biomedical co. LTD	Phase 2	——
NCT03766178	Study of Anti-PD-1 Antibody SHR-1210 Plus Nimotuzumab in the Treatment of Advanced Esophageal Squamous Cell Carcinoma	Esophageal Squamous Cell Carcinoma	Drug: Nimotuzumab + SHR-1210	The First Affiliated Hospital of Zhengzhou University	Phase 2	——

해외 바이오의약품 임상 현황 (2020.12.21~2021.1.3)

한국바이오의약품협회, 2021.1.5.
출처: ClinicalTrials.gov

NCT04672928	A Clinical Study to Evaluate the Efficacy and Safety of IBI318 in Combination With Paclitaxel Versus Placebo in Combination With Paclitaxel in Patients With Small Cell Lung Cancer Who Have Failed First-line or Above Chemotherapies	Small Cell Lung Carcinoma	Drug: paclitaxel Biological: IBI318	Innovent Biologics (Suzhou) Co. Ltd.	Phase 1	————
NCT04531865	Randomized Trial Evaluating Mycophenolate Mofetil in Children With Nephrotic Syndrome After Rituximab Treatment	Frequently Relapsing Nephrotic Syndrome Steroid-Dependent Nephrotic Syndrome	Drug: Rituximab Drug: Mycophenolate Mofetil Drug: Placebo tablets matching Mycophenolate Mofetil	Children's Hospital of Fudan University Xinhua Hospital, Shanghai Jiao Tong University School of Medicine Shanghai Children's Medical Center Shanghai Children's Hospital	Phase 3	————
NCT04661150	A Study of Atezolizumab and Trastuzumab in Combination With Capecitabine and Oxaliplatin in Patients With HER2 Positive Locally Advanced Resectable Gastric Cancer of Adenocarcinoma of Gastroesophageal Junction	Gastric Cancer Gastroesophageal Junction Adenocarcinoma	Drug: Atezolizumab Drug: Trastuzumab Drug: Capecitabine Drug: Oxaliplatin	Hoffmann-La Roche	Phase 2	————
NCT04622228	Study of Low-Dose Radiotherapy (LDRT) Concurrent Cisplatin/Carboplatin Plus Etoposide With Atezolizumab for Patients With Extensive-Stage Small Cell Lung Cancer	Carcinoma, Small Cell Lung	Drug: Atezolizumab Drug: Cisplatin Drug: Carboplatin Drug: Etoposide Radiation: Thoracic radiation therapy (TRT)	Hoffmann-La Roche	Phase 2	————
NCT04600947	Study of LP002 for the Treatment of Patients With Relapsed or Refractory Primary Mediastinal Large B-cell Lymphoma	Primary Mediastinal Large B-Cell Lymphoma (PMBCL)	Drug: LP002	Taizhou HoudeAoke Biomedical Co., Ltd.	Phase 2	————
NCT04629248	A Study Evaluating the Efficacy and Safety of Obinutuzumab in Participants With Primary Membranous Nephropathy	Primary Membranous Nephropathy	Drug: Obinutuzumab Drug: Tacrolimus Drug: Methylprednisolone Drug: Acetaminophen Drug: Diphenhydramine	Hoffmann-La Roche	Phase 3	————

○ 일본 1건

NCT Number	Title	Conditions	Interventions	Sponsor/Collaborators	Phases	출처 URL
NCT04676477	Patritumab Deruxtecan in Combination With Osimertinib in Subjects With Locally Advanced or Metastatic EGFR-mutated Non-Small Cell Lung Cancer	Non-Small Cell Lung Cancer (NSCLC)	Drug: Patritumab deruxtecan Drug: Osimertinib	Daiichi Sankyo, Inc.	Phase 1	————